Interim Results of a Phase II Study of Hypofractionated Radiotherapy with Concurrent Temozolomide Followed by Adjuvant Temozolomide in Patients over 70 Years Old with Newly Diagnosed Glioblastoma.

Academic Article


  • OBJECTIVE: In this phase II study, we investigate clinical outcomes and tolerability of hypofractionated radiotherapy (HRT) combined with temozolomide (TMZ) to treat elderly patients with glioblastoma (GBM). METHODS: Patients 70 years of age or older with newly diagnosed GBM received HRT to a dose of 34 Gy given in ten fractions over 2 weeks, delivered with concurrent and adjuvant TMZ. RESULTS: In this interim analysis, ten patients were enrolled on trial from 12/1/2015 to 4/5/2017. With a median follow-up of 9 months (range 3-12 months), median progression-free survival (PFS) was 6 months. The median overall survival (OS) has not been reached. Estimated 1-year OS and PFS rates were 53.3 and 44.4%, respectively. All patients completed the full course of RT, with no patients developing grade 3 or higher adverse events from treatment. CONCLUSIONS: The preliminary results of our phase II trial suggest HRT delivered over 2 weeks with concurrent and adjuvant TMZ is well tolerated in elderly patients with GBM without compromising clinical outcomes.
  • Authors


  • Clinical trial, Combined modality, Elderly, Glioblastoma, Hypofractionated, Radiation, Temozolomide, Aged, Aged, 80 and over, Antineoplastic Agents, Alkylating, Brain Neoplasms, Dacarbazine, Disease Progression, Disease-Free Survival, Female, Glioblastoma, Humans, Male, Quality of Life, Radiation Dose Hypofractionation, Surveys and Questionnaires, Temozolomide
  • Digital Object Identifier (doi)

    Author List

  • Yusuf M; Ugiliweneza B; Amsbaugh M; Boakye M; Williams B; Nelson M; Hattab EM; Woo S; Burton E
  • Start Page

  • 39
  • End Page

  • 42
  • Volume

  • 95
  • Issue

  • 1